scholarly journals Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Non-Invasive and Invasive Bladder Urothelial Carcinoma Effects of Zhuling Jisheng Decoction

2021 ◽  
Vol 2021 ◽  
pp. 1-21
Author(s):  
Chenyu Ma ◽  
Jianlong Wang ◽  
Na Zhao ◽  
Zhenya Pan ◽  
Yi Lu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Oral Bioavailability ◽  
Urothelial Cancer ◽  
Target Genes ◽  
Network Pharmacology ◽  
Cancer Resistance ◽  
Bladder Urothelial Carcinoma ◽  
Urothelial Bladder ◽  
The Impact

Zhuling Jisheng decoction is employed for the treatment of bladder urothelial cancer in clinical practice of traditional Chinese medicine. However, there are few studies on its precise mechanism. For the antibladder cancer action of Zhuling Jisheng decoction, a network pharmacological technique was used to design a component/target/pathway molecular regulatory network. The TCMSP dataset was used to identify the chemical makeup of Zhuling Jisheng decoction, which was then analyzed and assessed for oral bioavailability and pharmacological similarity. The chemical composition of Zhuling Jisheng decoction was identified through the TCMSP database, and it was evaluated and screened based on oral bioavailability and drug similarity. The GEO database was searched for genes associated with urothelial bladder carcinoma, and gene targets associated with bladder urothelial cancer resistance were chosen by comparison. The function and linked pathways of the target genes were examined and screened using annotation, visualization, and a comprehensive discovery database. The impact of Zhuling Jisheng decoction on urothelial bladder cancer was studied using Cytoscape software to create a component/target/pathway network. Finally, 69 and 55 target genes were discovered for noninvasive bladder urothelial cancer and invasive bladder urothelial cancer, respectively. In noninvasive urothelial cancer, 118 pathways were highly enriched, including the TNF signaling pathway and the IL-17 signaling route. 103 pathways were highly enriched in invasive urothelial cancer, including the p53 signaling route, bladder cancer route, and calcium signaling route. There were 18 and 15 drug targets associated with noninvasive and invasive bladder urothelial carcinoma prognoses. Many signaling pathways directly act on tumours, and indirect pathways inhibit the development of bladder urothelial carcinoma. This research establishes a scientific foundation for further research into the framework of action of Zhuling Jisheng decoction in the therapy of bladder urothelial cancer.

Treatment of metastatic bladder cancer

2017 ◽  
Author(s):  
Fabio Calabrò ◽  
Cora N. Sternberg
Keyword(s):  
Bladder Cancer ◽  
Urothelial Cancer ◽  
Clinical Investigation ◽  
Good Prognosis ◽  
New Drugs ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Molecular Patterns ◽  
The Impact

Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.

scholarly journals Vaginal metastasis of bladder urothelial carcinoma: Description of a case and revision of literature

2017 ◽  
Vol 89 (2) ◽  
pp. 156 ◽  
Author(s):  
Carmelo A. Di Franco ◽  
Daniele Porru ◽  
Giovanni Giliberto ◽  
Alessandra Viglio ◽  
Bruno Rovereto
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Vaginal Bleeding ◽  
Urothelial Cancer ◽  
Vaginal Wall ◽  
Rare Entity ◽  
Bladder Urothelial Carcinoma ◽  
Vaginal Metastasis ◽  
History Of

Vaginal metastases from urothelial cancer are a rare entity and in literature, few cases are described. We report a case of a 68 year-old woman with history of bladder urothelial carcinoma underwent to radical cystectomy who came in our department after 5 months for pelvic pain and vaginal bleeding. Objective examination revealed an ulcerative, solid vaginal lesion in the upper vaginal wall. We performed a vaginal biopsy that showed urothelial carcinoma compatible with the primitive bladder cancer. The patient underwent to surgery and was sent to oncological evaluation.

scholarly journals Unexpected Bladder Urothelial Carcinoma in a Young Adult-Case Report with Literature Review

2020 ◽  
pp. 1-3
Author(s):  
Hamdy Aboutaleb ◽  
Hamdy Aboutaleb
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Lateral Wall ◽  
Complete Removal ◽  
Heavy Smoking ◽  
Urothelial Bladder Carcinoma ◽  
Bladder Urothelial Carcinoma ◽  
Urothelial Bladder ◽  
History Of ◽  
Children And Young Adults

Background: Bladder cancer is the third most common malignancy in adults, accounting for 2.1% of all cancer-related deaths. Its highest incidence is in the 6th decade of life. Urothelial bladder cancer is rare in children and adolescents, presenting in only 0.003% of the population under 20 years of age. The aim of the paper is to report a rare case of bladder urothelial carcinoma in a young girl aged 27 years. Case Presentation: We report the case of a 27-year-old girl who presented with painless gross hematuria. She had a history of heavy smoking and recurrent cystitis. CT-KUB revealed polypoidal tumor in right lateral wall of the urinary bladder. Transurethral resection of the tumor was performed for complete removal of the tumor. Follow-up revealed no recurrence for two years. Conclusion: Urothelial bladder carcinoma should be excluded in children and young adults when they present with painless hematuria. Although this presentation is rare, its prognosis is good.

scholarly journals Prolonged survival in a patient with choroidal metastases from urothelial bladder cancer

2013 ◽  
Vol 3 (4) ◽  
pp. 36 ◽  
Author(s):  
Kirsty L. Wiltshire ◽  
Norman Laperriere ◽  
Robert G. Bristow
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Urothelial Cancer ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
History Of ◽  
Carcinoma Of The Bladder ◽  
Disease Free ◽  
New Onset

Choroidal metastases secondary to urothelial carcinoma areextremely rare and are usually associated with an extremely poorprognosis. We present a case of an 88-year-old man with newlydiagnosed urothelial carcinoma of the bladder who presented withacute loss of vision before commencing definitive concurrentchemoradiotherapy to the bladder. Ophthalmological examinationdemonstrated bilateral choroidal metastases. He received palliativeradiotherapy to the orbits and completed his planned radiotherapyto the bladder. He remained disease-free at last follow-up 4 yearsafter the completion of treatment. We review the literature particularlywith regard to diagnosis and management of choroidalmetastases. Choroidal metastases should be considered in a patientwith a history of urothelial cancer presenting with new onset ofeye symptoms.

The impact of histologic variants of urothelial carcinoma on clinical outcomes following trimodal bladder-preserving therapy.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 421-421
Author(s):  
Yoshiyuki Nagumo ◽  
Shuya Kandori ◽  
Tomokazu Kimura ◽  
Takashi Kawahara ◽  
Takahiro Kojima ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Clinical Outcomes ◽  
Invasive Bladder Cancer ◽  
Rank Test ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Significant Difference ◽  
Muscle Invasive ◽  
The Impact

421 Background: The current guidelines for muscle-invasive bladder cancer recommend the use of neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, a trimodal approach involving the combination of maximal transurethral resection (TUR) and combined chemoradiotherapy is an alternative in selected patients. Clinical outcomes of patients with histologic variants have not well been known. Methods: From 1990 to 2015, 148 patients with cT2-3N0M0 muscle-invasive bladder cancer underwent trimodal bladder-preserving therapy consisting of maximal TUR of the bladder tumor, intra-arterial chemotherapy and radiotherapy at our institution. We compared complete response rate (CRR) of bladder preservation, 5-yr cause-specific survival (CSS), and 5-yr overall survival (OS) for the patients with pure urothelial carcinoma (UC) or variant UC. OS and CSS were analyzed by using the Kaplan-Meier method and log-rank test. Results: The median follow-up was 38.3 months. All patients were T2-T3N0M0 (T2, n = 90; T3, n = 58). There were no significant differences in clinical characteristics between pure and variant UC groups. Eleven (7%) of the 148 patients had variant UC; 7 (64%) had UC with squamous and/or glandular differentiation, and 4 (36%) had other forms, including sarcomatoid (n = 1), plasmacytoid (n = 1), signet ring cell (n = 1), and clear cell variants (n = 1). There was no significant difference between pure UC and variant UC for CRR of bladder preservation (85% vs 82%, p = 0.66), the 5-yr CSS (88% vs 75%, p = 0.86) and the 5-yr OS (81% vs 75%, p = 0.66). Conclusions: Our findings indicate that trimodal bladder-preserving therapy can be an effective treatment option for selected muscle-invasive bladder cancer patients with variant UC.

Effect of contemporary health screening not focused on bladder cancer on diagnosis of bladder urothelial carcinoma

2017 ◽  
Vol 16 (3) ◽  
pp. e211
Author(s):  
Y.S. Suh ◽  
H.H. Sung ◽  
H.G. Jeon ◽  
B.C. Jeong ◽  
S.I. Seo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Health Screening ◽  
Bladder Urothelial Carcinoma

Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma and Urine from Patients with Bladder Cancer

2006 ◽  
Vol 21 (1) ◽  
pp. 6-11 ◽  
Author(s):  
M.N. Holten-Andersen ◽  
N. Brünner ◽  
H.J. Nielsen ◽  
I.J. Christensen ◽  
N. Møller Sørensen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Cancer ◽  
Tissue Inhibitor Of Metalloproteinases ◽  
Healthy Individuals ◽  
Tissue Inhibitor ◽  
Average Ratio ◽  
Healthy Donors ◽  
Urothelial Bladder ◽  
Urine Levels ◽  
Potential Use

Aim To assess the potential use of plasma and urine levels of tissue inhibitor of metalloproteinases 1 (TIMP-1) in urothelial cancer. Methods TIMP-1 levels were determined in urine and plasma from healthy donors (n=26), patients with bacterial bladder infection (n=24), urothelial bladder adenoma (n=3) or adenocarcinoma (n=7). Results Free and total TIMP-1 in plasma were weakly but significantly correlated with age; urinary TIMP-1 was not. A strong correlation between free and total TIMP-1 in plasma was observed, with an average ratio of 0.85. No correlation between total TIMP-1 in urine and plasma was found (p=0.55). No significant differences in free or total TIMP-1 in plasma were found between healthy individuals, patients with cystitis or bladder cancer (p=0.4). Urinary TIMP-1 levels were significantly increased in patients with cystitis (p=0.001). No apparent differences in TIMP-1 levels were found in patients with bladder cancer at different stages. Conclusion Our previous observation of a weak but significant correlation between plasma TIMP-1 and age was confirmed. Likewise, an association between free and total TIMP-1 in plasma with a ratio of 0.85 was established. No correlation between plasma and urine TIMP-1 was found. Measurement of TIMP-1 in plasma and/or urine is apparently not useful for the identification of bladder cancer.

Outcomes of radical cystectomy for micropapillary urothelial carcinoma at the University of Southern California.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 300-300
Author(s):  
Adrian Stuart Fairey ◽  
Siamak Daneshmand ◽  
Anne Schuckman ◽  
Gary Leiskovsky ◽  
Hooman Djaladat ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Survival Data ◽  
Southern California ◽  
Multivariable Analysis ◽  
University Of Southern California ◽  
Histologic Type ◽  
The University ◽  
The Impact

300 Background: The role of micropapillary urothelial carcinoma (MUC) variant histology as an independent prognostic factor for survival after radical cystectomy has not been studied. Our aim was to examine the impact of MUC on survival. Methods: A retrospective analysis of prospectively collected data from the University of Southern California (USC) Bladder Cancer Database was performed. Between 1985 and 2008, 1681 patients underwent radical cystectomy and extended pelvic lymph node dissection for primary bladder cancer. All surgical specimens underwent central pathologic review by dedicated genitourinary pathologists. Histologic type was categorized according to the WHO/ISUP 1998 classification as urothelial carcinoma (UC; n=1648) or MUC (n=33). The outcomes were overall survival (OS) and recurrence-free survival (RFS). The Kaplan-Meier method and Cox proportional regression models were used to analyze survival data. Results: The median follow-up duration was 10 years (range, 0 to 25 years). Baseline characteristics were similar between histologic types except MUC was associated with advanced clinical (cTanyN1-3: 2% versus 9%, p=0.03) and pathologic (pTanyN1-3: 23% versus 46%, p=0.01) TNM stage, multifocality (37% versus 58%, p=0.02), and high nuclear grade (84% versus 97%, p=0.04). The predicted 5-year OS (59% and 67%, Log rank p=0.79) and RFS (67% and 58%, Log rank p=0.50) rates did not differ between patients with UC and MUC. Multivariable analysis showed that histologic type was not independently associated with OS (HR 0.92, 95% CI 0.56 to 1.50, p=0.73) or RFS (HR 0.92, 95% CI 0.52 to 1.63, p=0.77). Conclusions: Outcomes of radical cystectomy for patients with MUC are similar to those with UC when controlling for other clinical and pathologic factors.

Mechanisms of Compound Kushen Injection for Treatment of Bladder Cancer Based on Bioinformatics and Network Pharmacology With Experimental Validation

2020 ◽  
Author(s):  
Lihui Zhang ◽  
Wanying Zhang ◽  
Jiaming Xiong ◽  
Xiumei Duan ◽  
Lina Hai ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Target Genes ◽  
Medicinal Preparation ◽  
Malignant Neoplasm ◽  
Enrichment Analysis ◽  
Functional Enrichment ◽  
Bladder Cancer Cell Line ◽  
Network Pharmacology ◽  
Therapeutic Effects ◽  
Gene And Protein Expression

Abstract Background: Bladder cancer is the most common malignant neoplasm of the urinary system. CompoundKushen injection (CKI) is a Chinese medicinal preparation that has been used clinically to treat varioustypes of cancers for more than 20 years. However, the pharmacological effect of CKI on bladder cancerrequires further clarification.Methods: Network pharmacology combined with bioinformatics was used to elucidate the therapeuticmechanism and potential targets of CKI in bladder cancer. The mechanism by which CKI is effective againstbladder cancer was further verified in vitro using the human bladder cancer cell line T24.Results: Network pharmacology analysis identified 35 active compounds and 268 target genes of CKI.Bioinformatics data mining revealed 5500 differentially expressed genes associated with bladder cancer.Common genes of CKI and bladder cancer suggested that CKI exerts anti-bladder cancer effects byregulating genes such as MMP-9, JUN, EGFR, and ERK1. Functional enrichment analysis indicated thatCKI has a therapeutic effect on bladder cancer by synergistically regulating certain biological processes,including cell proliferation, cell migration, and cell apoptosis. In addition, Kyoto Encyclopedia of Genes andGenomes enrichment analysis implicated pathways related to cancer, bladder cancer, and the PI3K-Aktsignaling pathway. Consistently, cell experiments indicated that CKI could inhibit proliferation andmigration of T24 bladder cancer cells, and induce their apoptosis. Moreover, RT-qPCR and western blotresults indicated that CKI may treat bladder cancer by downregulating gene and protein expression levels,respectively of MMP-9, JUN, EGFR, and ERK1.Conclusions: CKI can inhibit proliferation and migration, and induce apoptosis of T24 bladder cancer cellsthrough multiple biological pathways and targets. CKI also has significant effects on regulation of key genesand proteins associated with bladder cancer. Overall, our findings provide solid evidence and deepen currentunderstanding of the therapeutic effects of CKI for bladder cancer, and further support its clinical use.

Sign in / Sign up

Export Citation Format

Share Document